NYSE:MYOV - Myovant Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$25.10 +0.34 (+1.37 %)
(As of 06/21/2018 12:01 PM ET)
Previous Close$24.95
Today's Range$24.95 - $25.24
52-Week Range$9.92 - $25.28
Volume3,787 shs
Average Volume53,421 shs
Market Capitalization$1.54 billion
P/E Ratio-10.47
Dividend YieldN/A
Beta-2.15
Myovant Sciences logoMyovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MYOV
CUSIPN/A
Phone203-318-9709

Debt

Debt-to-Equity Ratio1.16
Current Ratio3.09
Quick Ratio3.09

Price-To-Earnings

Trailing P/E Ratio-10.47
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.62 per share
Price / Book40.48

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net IncomeN/A
Net MarginsN/A
Return on Equity-148.99%
Return on Assets-102.95%

Miscellaneous

Employees86
Outstanding Shares64,880,000

Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd (NYSE:MYOV) posted its quarterly earnings results on Tuesday, June, 12th. The company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.77) by $0.04. View Myovant Sciences' Earnings History.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Myovant Sciences.

What price target have analysts set for MYOV?

6 brokerages have issued 12 month price objectives for Myovant Sciences' stock. Their predictions range from $18.00 to $44.00. On average, they expect Myovant Sciences' share price to reach $26.75 in the next twelve months. View Analyst Ratings for Myovant Sciences.

What are Wall Street analysts saying about Myovant Sciences stock?

Here are some recent quotes from research analysts about Myovant Sciences stock:
  • 1. According to Zacks Investment Research, "Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. " (4/18/2018)
  • 2. Cowen Inc analysts commented, "Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of." (11/14/2017)

Who are some of Myovant Sciences' key competitors?

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the folowing people:
  • Dr. Lynn Seely, Chief Exec. Officer, Pres and Exec. Director (Age 59)
  • Mr. Frank L. Karbe, Principal Financial & Accounting Officer (Age 50)
  • Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 50)
  • Ms. Julie Tran MBA, MSHR, Exec. Director of HR
  • Mr. Bryan Selby, Sr. VP of Product Devel.

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Has Myovant Sciences been receiving favorable news coverage?

News headlines about MYOV stock have trended somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Myovant Sciences earned a news sentiment score of 0.10 on Accern's scale. They also assigned media coverage about the company an impact score of 47.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.63%), Eventide Asset Management LLC (0.94%), Lord Abbett & CO. LLC (0.24%), JPMorgan Chase & Co. (0.18%), Millennium Management LLC (0.18%) and Platinum Investment Management Ltd. (0.09%). Company insiders that own Myovant Sciences stock include Holdings Ltd Dexxon and Pharmaceuticals Interna Takeda. View Institutional Ownership Trends for Myovant Sciences.

Which major investors are selling Myovant Sciences stock?

MYOV stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Myovant Sciences.

Which major investors are buying Myovant Sciences stock?

MYOV stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Platinum Investment Management Ltd., Millennium Management LLC, Eventide Asset Management LLC, JPMorgan Chase & Co. and Swiss National Bank. Company insiders that have bought Myovant Sciences stock in the last two years include Holdings Ltd Dexxon and Pharmaceuticals Interna Takeda. View Insider Buying and Selling for Myovant Sciences.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $25.10.

How big of a company is Myovant Sciences?

Myovant Sciences has a market capitalization of $1.54 billion. Myovant Sciences employs 86 workers across the globe.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The company can be reached via phone at 203-318-9709 or via email at [email protected]


MarketBeat Community Rating for Myovant Sciences (MYOV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.